A pivotal Phase III trial combining Gilead Sciences’ Trodelvy (sacituzumab govitecan) with Merck & Co.’s Keytruda (pembrolizumab) has been terminated, signaling a significant setback for the potential expansion of Gilead’s flagship antibody-drug conjugate (ADC) in the lucrative non-small cell lung cancer (NSCLC) market. The decision, driven by an external data monitoring committee’s assessment, underscores the complex and often challenging landscape of oncology drug development and highlights the strategic recalibrations both pharmaceutical giants are undertaking.
The KEYNOTE-D46/EVOKE-03 study, a critical component of the companies’ collaboration, was designed to evaluate the efficacy of the Trodelvy-Keytruda combination as a first-line treatment for patients with PD-L1 expressing NSCLC. The external committee’s prediction that the combination would not demonstrate a statistically significant improvement in overall survival (OS) over Keytruda monotherapy led to the trial’s discontinuation. While the combination did show a numerically positive trend in progression-free survival (PFS), this benefit did not meet the stringent statistical thresholds required for success. Crucially, the investigational regimen was found to be well-tolerated, with no new safety concerns emerging, suggesting the biological rationale for the combination remains sound, even if its clinical impact in this specific setting proved elusive.
This outcome represents a notable hurdle for Gilead, which has been aggressively pursuing the expansion of Trodelvy’s indications, both as a standalone therapy and in combination with other agents, across a spectrum of solid tumors. The company has emphasized that this particular trial’s termination will not affect its ongoing studies exploring Trodelvy’s potential in other therapeutic areas. For Merck & Co., while a minor setback, it also prompts a re-evaluation of Keytruda’s combination strategies as the company braces for the drug’s eventual patent cliff.
The Trial’s Trajectory: A Path Diverted
The KEYNOTE-D46/EVOKE-03 study was initiated with considerable anticipation, representing a significant investment in exploring novel treatment paradigms for NSCLC, a disease notorious for its complex biology and the need for innovative therapeutic approaches. The rationale for combining an ADC like Trodelvy, which targets Trop-2 and delivers a cytotoxic payload, with an immune checkpoint inhibitor like Keytruda, which unleashes the body’s own immune system against cancer, was compelling. The synergistic potential of these two modalities offered the promise of enhanced anti-tumor activity and improved patient outcomes.
The trial enrolled a specific patient population: those with newly diagnosed, advanced NSCLC expressing programmed death-ligand 1 (PD-L1). This biomarker is often used to predict response to immunotherapy, and its presence suggested a higher likelihood of benefiting from Keytruda. The inclusion of Trodelvy aimed to overcome potential resistance mechanisms to immunotherapy and to directly target cancer cells, even those less susceptible to immune attack.
However, the external data monitoring committee’s review of interim data led to a somber conclusion. The committee’s statistical modeling indicated a low probability of the combination achieving its primary endpoint of improved OS. This decision, while disappointing, is a standard and crucial safeguard in clinical trial design, designed to prevent further exposure of patients to potentially ineffective treatments and to conserve valuable resources. The discontinuation of the study, therefore, reflects a commitment to rigorous scientific evaluation and patient safety.
Supporting Data: A Tale of Two Endpoints
The trial’s outcome was characterized by a divergence in the performance of its key endpoints. While the primary endpoint of overall survival did not show a statistically significant benefit for the combination, the progression-free survival (PFS) data presented a more nuanced picture. PFS measures the length of time during which a patient lives without their cancer worsening. The Trodelvy-Keytruda combination did demonstrate a numerical improvement in PFS compared to Keytruda alone, suggesting that the combination may have had some impact on slowing tumor growth or progression.
This additive effect on PFS, even if not statistically significant, is not entirely without merit. It indicates that the combination might offer some clinical benefit to patients, potentially delaying the need for subsequent lines of therapy. However, in the context of pivotal Phase III trials, statistical significance in primary endpoints is paramount, as it forms the basis for regulatory approval and widespread clinical adoption.
Furthermore, the safety profile of the combined regimen was deemed acceptable. The absence of new or unexpected safety signals is a positive indicator, suggesting that the tolerability of the combination aligns with expectations based on the known safety profiles of Trodelvy and Keytruda individually. This is crucial for future strategic considerations, as a manageable safety profile can facilitate the exploration of combinations in different patient populations or treatment settings.
Official Responses: Navigating the Setback
Both Gilead and Merck & Co. issued statements acknowledging the termination of the KEYNOTE-D46/EVOKE-03 study. Gilead, in particular, framed the decision as a strategic realignment rather than a definitive failure of Trodelvy. The company reiterated its commitment to Trodelvy’s broad development program, emphasizing that the results of this specific trial would not impede its ongoing efforts to explore the drug’s potential in other indications and treatment combinations.
"While we are disappointed with this outcome, we respect the decision of the external data monitoring committee," a Gilead spokesperson stated. "Our focus remains on advancing Trodelvy’s extensive development program across a range of cancers, where we continue to see promising results and a clear need for innovative treatment options."
Merck & Co., while also acknowledging the discontinuation, highlighted its ongoing commitment to advancing oncology research and development, particularly in lung cancer. The company continues to invest heavily in Keytruda’s broad label and explore novel combinations to extend its impact.
The measured responses from both companies reflect the high-stakes nature of pharmaceutical development. While a setback in one trial can be significant, it is rarely the sole determinant of a drug’s future. Strategic pivoting and a focus on other promising avenues are common practices in navigating the complexities of drug development.
Implications: A Shift in Focus and Future Prospects
The termination of the KEYNOTE-D46/EVOKE-03 trial carries several significant implications for both Gilead and Merck & Co., as well as for the broader landscape of oncology treatment.
For Gilead Sciences:
- Setback for Trodelvy’s NSCLC Ambitions: This result undoubtedly tempers expectations for Trodelvy’s immediate impact in the first-line NSCLC setting as a combination therapy. The drug’s expansion into this large and competitive market will likely rely on other avenues.
- Renewed Emphasis on Other Indications: The company will likely redouble its efforts on ongoing studies for Trodelvy in other solid tumors. This includes late-stage trials in extensive-stage small cell lung cancer (ES-SCLC) and second-line metastatic endometrial cancer, where the drug is already approved for certain indications.
- Strategic Realignment: This outcome may prompt Gilead to re-evaluate its combination strategies for Trodelvy, potentially focusing on patient populations or disease settings where the synergistic benefit with immunotherapy is more pronounced or where alternative combination partners may prove more fruitful.
- Financial Considerations: While Trodelvy has demonstrated strong sales growth, reaching $457 million in Q2 2026, a 26% year-on-year increase, the inability to secure a first-line NSCLC indication represents a missed opportunity for substantial revenue acceleration.
For Merck & Co.:
- Minor Impact on Keytruda’s Dominance: Keytruda remains a cornerstone of cancer treatment, with approvals in over 20 cancer types. The discontinuation of this single trial is unlikely to significantly alter its market position in the short term.
- Accelerating Pipeline Diversification: The impending patent cliff for Keytruda in 2028 underscores Merck’s urgent need to diversify its oncology pipeline. The company is actively investing in next-generation therapies, including ADCs.
- Focus on Sacituzumab Tirumotecan (Sac-TMT): Merck’s strategic interest in the TROP2-targeting ADC developed by Kelun Biotech, sacituzumab tirumotecan (sac-TMT), gains further prominence. Sac-TMT has shown positive Phase III results in NSCLC and endometrial cancer, with analysts projecting blockbuster status by 2029. This trial’s outcome may indirectly bolster the perceived value of other TROP2-targeting agents.
Broader Oncology Landscape:
- Complexity of Combination Therapies: The trial’s failure serves as a reminder of the inherent complexity in developing effective combination therapies. Optimizing the synergy between different drug classes, understanding resistance mechanisms, and identifying the right patient populations are critical challenges.
- The Promise of ADCs: Despite this setback, the potential of antibody-drug conjugates like Trodelvy remains significant. The drug’s approved indications and its continued exploration in other settings underscore its therapeutic value.
- The Enduring Importance of Monotherapy: The trial’s outcome also highlights the continued relevance of monotherapy approaches. Keytruda’s success as a standalone treatment in many indications demonstrates the power of immunotherapy.
- Future of TNBC: With the NSCLC trial terminated, Gilead and MSD will now heavily focus on the ASCENT-05 trial (NCT05633654). This study is evaluating the Trodelvy-Keytruda combination against physician’s choice treatment in patients with high-risk, adjuvant triple-negative breast cancer (TNBC). A positive outcome here could offer a significant win for both companies and a vital new treatment option for TNBC patients.
In conclusion, the termination of the KEYNOTE-D46/EVOKE-03 trial represents a significant, albeit not insurmountable, challenge for Gilead and Merck & Co. It underscores the iterative and often unpredictable nature of oncology drug development. While the immediate aspirations for Trodelvy in first-line NSCLC have been curtailed, both companies possess robust pipelines and are strategically positioned to adapt. The focus now shifts to other promising avenues, particularly the ongoing ASCENT-05 trial in TNBC, where the combination may yet find its decisive victory. The pharmaceutical industry continues to learn and evolve, with each trial, successful or otherwise, contributing valuable knowledge to the ongoing quest for more effective cancer therapies.
About the Author
